Case report: Generalized granuloma annulare successfully treated with baricitinib in two cases

Treatments are challenging in generalized granuloma annulare. We reported two cases of generalized granuloma annulare without diabetes mellitus; one exhibited non-annular papules and the other did patch/annular lesions. Since they were refractory to multiple treatments, we treated them with JAK inhi...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cutaneous immunology and allergy 2025-01, Vol.7
Main Authors: Yunoki, Marina, Kondo, Shumpei, Otsuka, Masaki, Tokura, Yoshiki
Format: Article
Language:English
Subjects:
abrocitinib
baricitinib
granuloma annulare
JAK inhibitor
upadacitinib
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Treatments are challenging in generalized granuloma annulare. We reported two cases of generalized granuloma annulare without diabetes mellitus; one exhibited non-annular papules and the other did patch/annular lesions. Since they were refractory to multiple treatments, we treated them with JAK inhibitor baricitinib at 2 mg daily. After 1–2-month treatment, they responded well to baricitinib with good tolerance. Given increased JAK1 signaling, high interferon-α and -γ production and macrophage activation in granuloma annulare, JAK inhibitors are considered to be a reasonable choice for recalcitrant generalized granuloma annulare. In addition to the reported cases, our two cases further support the effectiveness of JAK inhibitors for generalized granuloma annulare.
ISSN:2574-4593
2574-4593
DOI:10.3389/jcia.2024.13892